Tool for the Detection of Oncogeriatric Fragility in Patients Aged ≥75 Years Undergoing Oncological Treatment.(D-FOG)

NCT03261128 | Completed

• 1 other identifier: 2017-A02188-45
• Study Type: observational
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

Many cancers are diagnosed after 75 years. Treatment in chemotherapy begins without evidence of geriatric risk factors. A new tool for screening for geriatric fragilities is used, a self-administered questionnaire carried out by the patient before each chemotherapy cure. The objective is to secure the quality of patient care and to detect the appearance and / or aggravation of geriatric fragilities.

Conditions

75 Years Old and More; Cancer; Chemotherapy

Keywords

cancer; chemotherapy

Outcome Measures

Primary Outcomes (1)

• Evaluation of the feasibility of a new geriatric fragility screening tool (D-FOG) in patients aged ≥ 75 years during oncological treatment.

  Feasibility of D-FOG for patients : number of D-FOGs filled in, regularity of the D-FOG self-questionnaire by the patient, number of criteria entered by D-FOG, criterion analysis of D-FOG

  3 months

Study Arms (1)

Group D-FOG

Filling of a self-questionnaire before each chemotherapy cure

Other: Self-questionnaire

Interventions

Self-questionnaire OTHER

Filling of a self-questionnaire before each chemotherapy cure

Group D-FOG

Eligibility Criteria

• Age: 75 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients aged 75 years and over Cancer and treated with chemotherapy

You may qualify if:

• Patients aged 75 years and over
• Carriers of diagnosed cancer (excluding hematology)
• Whatever the location, uniqueness or multiple, duration of development and treatment status (adjuvant, neoadjuvant, locally advanced or metastatic)
• Seen in nursing consultant
• Beginning an oncological treatment
• Supported for oncology day hospital (HDJ) or weekly (HDS) chemotherapy
• Patient not opposed to participate in the study

You may not qualify if:

• Patients under 75 years of age
• Having not had an IDE ad consultation
• During oncological treatment
• Receiving Oral Therapy or hormone therapy alone
• Treated by radiotherapy alone or surgery alone
• Not attending a day or week oncology hospital
• Refusal to participate in research

Sponsors & Collaborators

• Poitiers University Hospital: lead

Study Sites (1)

CHU

Poitiers, 86000, France

Location

MeSH Terms

Conditions

Neoplasms

Study Officials

• VALERO SV SIMON, Doctor

  CHU Poitiers

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 4, 2017
• First Posted: August 24, 2017
• Study Start: November 21, 2017
• Primary Completion: September 11, 2018
• Study Completion: December 5, 2018
• Last Updated: January 29, 2019

Record last verified: 2019-01

Locations

FR (1)